RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System
September 18, 2020
Salt Lake City-based RenalytixAI, today announced the commercial launch of the KidneyIntelX clinical test reporting platform within the Mount Sinai Health System. This means that KidneyIntelX risk assessment of progressive decline in kidney function or kidney failure, including education support for treating clinicians, is now commercially available for patients with early stage diabetic kidney disease (DKD).
“This development underscores the leadership of RenalytixAI in addressing chronic kidney disease, from diagnosis to drug discovery,” said Kelvyn Cullimore, president and CEO of BioUtah.
RenalytixAI plans to continue to add to the quality and capability of the KidneyIntelX platform, designed to provide potentially critical new information about the rate of disease progression and risk of kidney failure in early stage kidney disease. Last month, the company announced a study with Mt. Sinai to monitor and predict kidney risk in COVID-19 patients.
Recent News
- Collaboration with Quest Diagnostics to expand kidneyintelX.dkd TM testing in the United States
- Utah Business Innovation Awards Summit Recap
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
